NEW YORK (GenomeWeb News) – Foundation Medicine reported after the close of the market Wednesday that its first quarter revenues rose 121 percent from the first quarter of 2013 and 19 percent sequentially, driven by sales of its FoundationOne and FoundationOne Heme cancer tests.

The Cambridge, Mass.-based cancer genomic analysis firm reported total revenues of $11.5 million for the three months ended March 31, up from $5.2 million in Q1 2013 and $9.7 million in Q4 2013. It beat the consensus Wall Street estimate of $11.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.